Table 2 Clinical features of TP53 mutant versus TP53/USP8 wild type and USP8 mutant groups
From: TP53 mutations in functional corticotroph tumors are linked to invasion and worse clinical outcome
Variable | TP53 mutant | TP53/USP8 wild type | P-value | USP8 mutant | P-valuea | ||||
|---|---|---|---|---|---|---|---|---|---|
Age at diagnosis (years), mean ± SD | 53 | ± 18 | 43 | ± 15 | 0.069 | 37 | ± 13 | 0.024 | b |
Sex (female), n (%) | 6/9 | (67%) | 31/52 | (73%) | 1.000 | 25/25 | (100%) | ≥ 0.001 | c,d |
BMI (kg/m2), mean ± SD | 30.6 | ± 6.0 | 28.4 | ± 5.6 | 0.312 | 29.0 | ± 7.8 | 0.641 | |
Disease presentation, n (%) | 0.065 | 0.060 | |||||||
CD | 5/9 | (56%) | 44/52 | (85%) | 17/25 | (68%) | |||
CTP-BADX/NS | 4/9 | (44%) | 8/52 | (15%) | 8/25 | (32%) | |||
Number of prior pituitary surgeries, n (%) | 0.009 | 0.034 | c | ||||||
0 | 2/9 | (22%) | 31/46 | (67%) | 17/25 | (68%) | |||
1 | 4/9 | (44%) | 13/46 | (28%) | 6/25 | (24%) | |||
≥ 2 | 3/9 | (33%) | 2/46 | (4%) | 2/25 | (8%) | |||
Total number of pituitary surgeries, n (%) | 0.018 | 0.109 | |||||||
1 | 2/9 | (22%) | 29/48 | (60%) | 15/25 | (60%) | |||
2 | 3/9 | (33%) | 14/48 | (29%) | 6/25 | (24%) | |||
≥ 3 | 4/9 | (44%) | 5/48 | (10%) | 4/25 | (16%) | |||
Complete tumor resection, n (%) | 1/8 | (13%) | 17/28 | (61%) | 0.041 | 14/17 | (82%) | 0.003 | b |
Postoperative remission, n (%) | 4/9 | (44%) | 28/46 | (61%) | 0.467 | 14/23 | (61%) | 0.670 | |
Postoperative tumor control, n (%) | 4/8 | (50%) | 14/26 | (54%) | 1.000 | 16/23 | (70%) | 0.494 | |
Radiation therapy, n (%) | 7/9 | (78%) | 10/38 | (26%) | 0.007 | 7/23 | (30%) | 0.014 | c |
Radiation therapy before sample collection, n (%) | 3/8 | (38%) | 2/30 | (7%) | 0.053 | 2/15 | (13%) | 0.074 | |
Bilateral adrenalectomy, n (%) | 4/9 | (44%) | 9/52 | (17%) | 0.065 | 10/25 | (40%) | 0.048 | |
Pharmacological treatmentse, n (%) | 4/6 | (67%) | 10/23 | (44%) | 0.390 | 4/14 | (29%) | 0.299 | |
Preoperative hormone levels | |||||||||
Plasma ACTH (pg/ml), median (IQR) | 105 | (741.0) | 96 | (253.4) | 0.821 | 100 | (944.4) | 0.902 | |
Serum cortisol (µg/dl), median (range) | 29 | (19) | 23 | (2197) | 1.000 | 196 | (2469) | 0.061 | |
24 h-urinary free cortisol (µg/24 h), median (range) | 1680 | (2860) | 433 | (10,806) | 0.674 | 447 | (2735) | 0.809 | |
Serum cortisol after low-dose DST (µg/dl), median (IQR) | 8.9 | (24.2) | 20.0 | (14.3) | 0.638 | 31.0 | (156.9) | 0.217 | |
Postoperative hormone levels | |||||||||
Plasma ACTH (pg/mL), median (IQR) | 106.0 | (216.0) | 17.8 | (89.5) | 0.192 | 20.0 | (78.5) | 0.341 | |
Serum cortisol nadir (µg/dl), median (range) | 5.7 | (20.8) | 7.8 | (18.3) | 0.907 | 20.0 | (33.3) | 0.253 | |
Disease-specific death, n (%) | 3/7 | (43%) | 1/26 | (4%) | 0.023 | 1/25 | (4%) | 0.010 | |